Apixaban is currently the most prescribed oral anticoagulant in the general population and in people with HIV. For people with HIV and atrial fibrillation (Afib or AF), ...

Apixaban is a direct-acting oral anticoagulant that has an excellent risk–benefit profile for stroke prevention among patients with clinical atrial fibrillation. 3,5 The Apixaban for the ...

Apixaban oral tablet is a prescription drug used to treat and prevent blood clots such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It also helps decrease risk of stroke in atrial ...

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

Observational data show rivaroxaban is associated with higher ischemic and hemorrhagic events vs apixaban and may provide 'reasonable assurance' that apixaban is safer and more effective ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

Phase 3 Data Published Today in The New England Journal of Medicine PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today ...

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

Rivaroxaban (Xarelto) was also associated with higher risk than apixaban (42.94 vs 20.05 per 1,000 person-years, HR 2.15, 95% ...